HeartSciences Inc. (HSCS) Cash & Equivalents (2022 - 2026)

HeartSciences (HSCS) has reported Cash & Equivalents for 5 consecutive years, with $1.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash & Equivalents rose 54.55% year-over-year to $1.7 million; the trailing twelve-month figure through Apr 2026 stood at $1.7 million (up 54.55% YoY), and the FY2026 full-year result was $1.7 million, up 54.55% from the prior year.
• Cash & Equivalents improved to $1.7 million in Q2 2026 per HSCS's latest filing, from $1.1 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $7.1 million in Q1 2024 and bottomed at $100144.0 in Q4 2023.
• Historically, Cash & Equivalents has averaged $2.7 million across 5 years, with a median of $2.0 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents tumbled 96.74% in 2023, then soared 3946.29% in 2024.
• Over 5 years, Cash & Equivalents stood at $3.1 million in 2022, then sank by 96.74% to $100144.0 in 2023, then jumped by 3946.29% to $4.1 million in 2024, then slumped by 72.9% to $1.1 million in 2025, then soared by 54.81% to $1.7 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $1.7 million, $1.1 million, and $2.0 million for Q2 2026, Q4 2025, and Q4 2025 respectively.